Applications | GO2 Healthcare Provider Portal

You must be a current COE Member and logged into your account to view this content.

Don’t have an account? Sign up.

Nodule Reporting	Yes
Nodule Review Board / MDT	Yes
Communication Process	Yes
Cessation Support	Yes
Total number of patients with incidental pulmonary nodule(s) who received follow-up imaging by LDCT protocol (radiation dose is < 3 mGy CTDIvol for individuals with below normal or normal BMI) in	5,978
Total patients with incidental pulmonary nodule(s) completing follow-up CT imaging in	0
LDCT Protocol Compliance Rate %	0
Comments	Awaiting results for follow up scans
Tracking Adherence	Yes
Select all that apply	Manual tracking (Excel, etc.)
Outcomes Review	Yes
Select all that apply	Internal quality outcomes data and metrics capturing policies and procedures, Established internal quality dashboard
Surgical lung resections with benign (nonmalignant) pathology in patients with IPN in	0
Total surgical lung resections in patients with IPN in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in patients with IPN in	0
Total nonsurgical lung biopsies in patients with IPN in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
Score	6
Qualification Status	Qualified
Institutional Workflows	No
Institutional Tools	Yes
Comments	All scans are reviewed by providers.
Select all that apply	Other (free text)
Name	Deborah Snead Abu-Alrub DNP, CRNP, AOCNP
Title	Director of Patient Programs
Email	daa@ccihsv.com
Phone	(256)-289-4124
User ID	Deb Abu-Alrub
Facility ID	1573

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, NCCN, ASCO
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, ASTRO, NCCN
Thoracic Oncology	Yes
Select all that apply	NCCN, TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	ASCO, NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Central or state cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	No
Comments	No surgeons associated with Clearview Cancer Institute
Name	Deborah Snead Abu-Alrub DNP, CRNP, AOCNP,
Title	Director of Patient Programs
Email	daa@ccihsv.com
Phone	(256)-289-4124
User ID	Deb Abu-Alrub
Facility ID	1573

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	2,749
Total number of people screened in	2,749
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	645
Total number of people who received baseline screening LDCT scans in (with and without SDM)	645
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	1,571
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	1,677
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	43
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	45
Follow-up Rate %	96
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	19
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	19
Follow-up Rate %	100
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	18
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	20
Follow-up Rate %	90
Surgical lung resections with benign (nonmalignant) pathology in	5
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	38
Nonmalignant Resection Rate %	13
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	23
Total nonsurgical lung biopsies in	156
Nonmalignant/Nondiagnostic Biopsy Rate %	15
	No
	Yes
Stage I	10
Stage II	1
Stage III	3
Stage IV	1
Stage I %	67
Stage II %	7
Stage III %	20
Stage IV %	7
Total screen-detected lung cancers	15
Name	Deborah Snead Abu-Alrub DNP, CRNP, AOCNP
Title	Director of Patient Programs
Email	daa@ccihsv.com
Phone	(256)-289-4124
User ID	Deb Abu-Alrub
Facility ID	1573

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Becky Bonds
Title	Lung and Chest Center Supervisor
Email	becky.bonds@ascension.org
Phone	(615)-284-7338
User ID	Becky Bonds
Facility ID	1122

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Becky Bonds
Title	Lung and Chest Program Supervisor
Email	becky.bonds@ascesnion.org
Phone	(615)-284-7338
User ID	Becky Bonds
Facility ID	1122

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Becky Bonds
Title	Chest and Lung Program Supervisor
Email	becky.bonds@ascension.org
Phone	(615)-284-7338
User ID	Becky Bonds
Facility ID	1120

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	1,383
Total number of people screened in	1,425
Screen-eligible Rate	97
Screen by which criteria (select all that apply)	CMS, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	0
Total number of people who received baseline screening LDCT scans in (with and without SDM)	0
SDM Documentation Rate	0
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	1,024
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	1,378
Follow-up Rate %	74
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	29
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	37
Follow-up Rate %	78
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	32
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	33
Follow-up Rate %	97
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	42
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	44
Follow-up Rate %	95
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I	6
Stage II	2
Stage III	2
Stage IV	3
Stage I %	46
Stage II %	15
Stage III %	15
Stage IV %	23
Total screen-detected lung cancers	13
Name	Stephanie Terrell
Title	Lung Navigator
Email	slterrell@mercy.com
Phone	(513)-870-7738
User ID	Stephanie Terrell
Facility ID	1362

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1654

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Thoracic Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Hospital-based cancer registry, Central or state cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1654

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Thoracic Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Hospital-based cancer registry, Central or state cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1660

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1660

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1663

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1809

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1665

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1664

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1661

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1662

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	3,147
Total number of people screened in	3,147
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	1,030
Total number of people who received baseline screening LDCT scans in (with and without SDM)	1,030
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	2,117
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	2,487
Follow-up Rate %	85
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	108
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	280
Follow-up Rate %	39
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	64
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	112
Follow-up Rate %	57
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	75
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	88
Follow-up Rate %	85
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	16
Total nonsurgical lung biopsies in	39
Nonmalignant/Nondiagnostic Biopsy Rate %	41
	Yes
	Yes
Stage I	19
Stage II	1
Stage III	5
Stage IV	5
Stage I %	63
Stage II %	3
Stage III %	17
Stage IV %	17
Total screen-detected lung cancers	30
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1659

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Thoracic Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Hospital-based cancer registry, Central or state cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Megan Shanahan
Title	Oncology Nurse Navigator
Email	megan.m.shanahan@powershealth.org
Phone	(219)-703-2332
User ID	Megan Shanahan
Facility ID	1659

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	402
Total number of people screened in	442
Screen-eligible Rate	91
Screen by which criteria (select all that apply)	CMS, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	131
Total number of people who received baseline screening LDCT scans in (with and without SDM)	131
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	0
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	0
Follow-up Rate %	0
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	18
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	21
Follow-up Rate %	86
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	11
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	11
Follow-up Rate %	100
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	6
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	6
Follow-up Rate %	100
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	1
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I	5
Stage II	0
Stage III	1
Stage IV	0
Stage I %	83
Stage II %	0
Stage III %	17
Stage IV %	0
Total screen-detected lung cancers	6
Name	Laurel McNish
Title	RN Clinical Coordinator
Email	laurel.mcnish@commonspirit.org
Phone	(720)-321-0158
User ID	Laurel McNish
Facility ID	1721

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kelly Pressler
Title	RN Director
Email	kpressler@redeemerhealth.org
Phone	(215)-938-3555
User ID	Ashlee Chapman
Facility ID	1428

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Ashlee Chapman
Title	RN
Email	achapman@holyredeemer.com
Phone	(215)-938-3551
User ID	Ashlee Chapman
Facility ID	1428

Patients with lung cancer (Stage IB and higher) who receive biomarker testing at the time of diagnosis in	0
Total patients diagnosed with lung cancer (Stage IB and higher) in	0
Biomarker Testing at Diagnosis Rate %	0
Comments	We complete NGS/biomarker testing on any IR or IP biopsy sampling completed for Stage IB and above; however this data is not tracked directly. We also complete on all surgical resections as well meeting IB or above criteria, this is order at 14 days post-discharge to accommodate insurance/medicare rules. We will work on making this a tracked metric for 2026 and 2027
Results Documented	Yes
Testing Before Systemic Therapy	Yes
Patients with disease progression on targeted therapy or immunotherapy +/- chemo who receive biomarker testing in	0
Total patients with disease progression on targeted therapy or immunotherapy +/- chemo in	0
Progression Biomarker Testing Rate %	0
Comments	We complete NGS/biomarker testing on any recurrent/progression patient if new tissue sampling completed; however this data is not tracked directly We will work on making this a tracked metric for 2026 and 2027
Clinical Trials Review	Yes
Referral Testing	Yes
Liquid Biopsy	Yes
Negative Liquid Biopsy Tissue	Yes
Score	6
Qualification Status	Qualified
Checkpoint Inhibitors	Yes
Comprehensive Testing	Yes
Name	Eric Bernicker
Title	Executive Medical Director of Oncology - Mountain Region
Email	eric.bernicker@commonspirit.org
Phone	(720)-627-4840
User ID	Laurel McNish
Facility ID	1721

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, NCCN, ASCO
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, ASTRO, NCCN
Thoracic Oncology	Yes
Select all that apply	AATS, ESMO, NCCN, STS, TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	CAP, NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Hospital-based cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Laurel McNish
Title	RN Clinical Coordinator
Email	laurel.mcnish@commonspirit.org
Phone	(720)-321-0158
User ID	Laurel McNish
Facility ID	1721

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	742
Total number of people screened in	742
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	126
Total number of people who received baseline screening LDCT scans in (with and without SDM)	126
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	145
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	361
Follow-up Rate %	40
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	9
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	13
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	4
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	5
Follow-up Rate %	80
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	2
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	2
Follow-up Rate %	100
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	3
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	1
Nonmalignant/Nondiagnostic Biopsy Rate %	0
Stage I	3
Stage II	0
Stage III	0
Stage IV	1
Stage I %	75
Stage II %	0
Stage III %	0
Stage IV %	25
Total screen-detected lung cancers	4
Name	Keith Mortman, MD
Title	Chief, Thoracic Surgery
Email	kmortman@mfa.gwu.edu
Phone	(202)-741-3220
User ID	Keith Mortman
Facility ID	1008

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, ASTRO, NCCN
Thoracic Oncology	Yes
Select all that apply	NCCN, TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	CAP
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Select all that apply	Central or state cancer registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Arlyn Arseneaux
Title	Direcor of Cancer Services
Email	aarseneaux@stph.org
Phone	(985)-338-5018
User ID	Megan Broussard
Facility ID	1299

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	1,811
Total number of people screened in	1,811
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	480
Total number of people who received baseline screening LDCT scans in (with and without SDM)	480
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	1,132
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	1,346
Follow-up Rate %	84
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	136
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	178
Follow-up Rate %	76
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	56
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	66
Follow-up Rate %	85
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	45
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	46
Follow-up Rate %	98
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	7
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	8
Total nonsurgical lung biopsies in	31
Nonmalignant/Nondiagnostic Biopsy Rate %	26
	Yes
Stage I	15
Stage II	2
Stage III	3
Stage IV	3
Stage I %	65
Stage II %	9
Stage III %	13
Stage IV %	13
Total screen-detected lung cancers	23
Name	Megan S Broussard
Title	Lung Cancer Screening Program Coordinator
Email	mbroussard@stph.org
Phone	(985)-871-5764
User ID	Megan Broussard
Facility ID	1299

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Melissa Aune
Title	Health Program Coordinator
Email	melissa.aune@sanfordhealth.org
Phone	(701)-234-5308
User ID	Melissa Aune
Facility ID	1247

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Melissa Aune
Title	Health Program Coordinator
Email	melissa.aune@sanfordhealth.org
Phone	(701)-234-5308
User ID	Melissa Aune
Facility ID	1247

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	Eligibility criteria including both USPSTF and that based on Tammemagi criteria
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	Conducted via pulmonary registered nurse
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	LungRADS
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Screening cases are shared regularly at our internal weekly nodule board and daily multidisciplinary lung tumor board.
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Comments	Screening results are reviewed by a pulmonary provider; if the LungRADS is less than 4, a templated letter is sent to the patient with screening recommendations. If the LungRADS is 4, the pulmonary provider personally communicates results and next steps with the patient via phone visit.
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Robert Anderson
Title	Nurse Practitioner
Email	anderson.robert2@mayo.edu
Phone	(507)-284-4341
User ID	Robert Anderson
Facility ID	2225

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Annie Lally
Title	Lung Cancer Screening Program Manager
Email	ann_m_lally@rush.edu
Phone	(312)-563-2360
User ID	Annie Lally
Facility ID	1680

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Annie Lally
Title	Lung Cancer Screening Program Manager
Email	ann_m_lally@rush.edu
Phone	(312)-563-2360
User ID	Annie Lally
Facility ID	1363

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Annie Lally
Title	Lung Cancer Screening Program Manager
Email	ann_m_lally@rush.edu
Phone	(312)-563-2360
User ID	Annie Lally
Facility ID	1681

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Annie Lally
Title	Lung Cancer Screening Program Manager
Email	ann_m_lally@rush.edu
Phone	(312)-563-2360
User ID	Annie Lally
Facility ID	1364

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	673
Total number of people screened in	673
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	268
Total number of people who received baseline screening LDCT scans in (with and without SDM)	268
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	383
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	383
Follow-up Rate %	100
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	19
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	37
Follow-up Rate %	51
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	11
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	17
Follow-up Rate %	65
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	5
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	6
Follow-up Rate %	83
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	1
Nonmalignant/Nondiagnostic Biopsy Rate %	0
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Haley Larkin
Title	BSN, RN
Email	haley.larkin@commonspirit.org
Phone	(719)-557-4408
User ID	Haley Larkin
Facility ID	1942

Patient Discussion	Yes
Biomarker Testing	Yes
Medical Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, NCCN, ASCO
Radiation Oncology	Yes
Select all that apply	TNM Stage Classification for Lung Cancer, NCCN
Thoracic Oncology	Yes
Select all that apply	AATS, ACCP, ESMO, NCCN, SSO, STS, TNM Stage Classification for Lung Cancer
Pathology	Yes
Select all that apply	CAP, NCCN
Multidisciplinary Team	Yes
Care Plan	Yes
Cancer Registry	Yes
Comments	National Cancer Database through the American College of Surgeons Commission on Cancer.
Select all that apply	Hospital-based cancer registry, Central or state cancer registry, Special-purpose (internal or external) registry
Cessation Support	Yes
Score	10
Qualification Status	Qualified
Outcomes Review	Yes
Board Certified	Yes
Name	Laura Kuzma
Title	Admin Director, Oncology and Clinical Trails
Email	lkuzma@firsthealth.org
Phone	(910)-715-2298
User ID	Kim Cobb
Facility ID	1296

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	2,234
Total number of people screened in	2,234
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	0
Total number of people who received baseline screening LDCT scans in (with and without SDM)	0
SDM Documentation Rate	0
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	No
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	1,687
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	0
Follow-up Rate %	0
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	0
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	172
Follow-up Rate %	0
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	0
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	93
Follow-up Rate %	0
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	0
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	10
Follow-up Rate %	0
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	No
	Yes
Stage I	19
Stage II	2
Stage III	0
Stage IV	7
Stage I %	68
Stage II %	7
Stage III %	0
Stage IV %	25
Total screen-detected lung cancers	28
Name	Tiffany English
Title	Lung Nodule Navigator
Email	tenglish@mhsystem.org
Phone	(740)-376-1979
User ID	Tiffany English
Facility ID	1244

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	BethAnn Kowalski
Title	RN Lung Nurse Navigator
Email	bethann.kowalski@nysmha.org
Phone	(518)-839-0566
User ID	BethAnn Kowalski
Facility ID	2221

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	BethAnn Kowalski
Title	RN Lung Nurse Navigator
Email	bethann.kowalski@nysmha.org
Phone	(518)-839-0566
User ID	BethAnn Kowalski
Facility ID	2222

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	No
Comments	Not sure if this is being audited to verify that it is done 100% of the time.
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	6
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leticia Riley
Title	Lung Nodule Program Nurse Navigator
Email	Leticia.riley@ascension.org
Phone	(512)-324-3340
User ID	Leticia Riley
Facility ID	2220

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	No
Comments	Not sure if everyone that is screened is getting this, but I believe they are.
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leticia Riley
Title	Lung Nodule Program Nurse Navigator
Email	Leticia.riley@ascension.org
Phone	(512)-324-3340
User ID	Leticia Riley
Facility ID	2220

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Whitney Mendel
Title	Community Outreach and Engagement Manager
Email	whitney.mendel@RoswellPark.org
Phone	(716)-845-1300
User ID	Whitney Mendel
Facility ID	1741

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Whitney Mendel
Title	Community Outreach and Engagement Manager
Email	whitney.mendel@RoswellPark.org
Phone	(716)-845-1300
User ID	Whitney Mendel
Facility ID	2008

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	590
Total number of people screened in	590
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	167
Total number of people who received baseline screening LDCT scans in (with and without SDM)	167
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	202
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	214
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	38
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	41
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	16
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	23
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	10
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	14
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1236

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	590
Total number of people screened in	590
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	214
Total number of people who received baseline screening LDCT scans in (with and without SDM)	214
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	259
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	274
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	49
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	53
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	21
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	30
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	12
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	18
Follow-up Rate %	67
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1237

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	661
Total number of people screened in	661
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	311
Total number of people who received baseline screening LDCT scans in (with and without SDM)	311
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	377
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	399
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	71
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	77
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	30
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	43
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	18
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	26
Follow-up Rate %	69
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1981

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	557
Total number of people screened in	557
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	185
Total number of people who received baseline screening LDCT scans in (with and without SDM)	185
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	224
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	237
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	42
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	45
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	18
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	26
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	11
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	16
Follow-up Rate %	69
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1979

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	473
Total number of people screened in	473
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	165
Total number of people who received baseline screening LDCT scans in (with and without SDM)	165
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	200
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	212
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	38
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	41
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	16
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	23
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	10
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	14
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1507

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	419
Total number of people screened in	419
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	172
Total number of people who received baseline screening LDCT scans in (with and without SDM)	172
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	208
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	220
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	39
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	42
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	17
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	24
Follow-up Rate %	71
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	10
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	14
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1235

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	533
Total number of people screened in	533
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	207
Total number of people who received baseline screening LDCT scans in (with and without SDM)	207
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	251
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	266
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	47
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	51
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	20
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	29
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	12
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	17
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1976

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	517
Total number of people screened in	517
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	234
Total number of people who received baseline screening LDCT scans in (with and without SDM)	234
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	283
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	300
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	53
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	57
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	23
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	33
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	14
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	20
Follow-up Rate %	70
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1506

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	820
Total number of people screened in	820
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	332
Total number of people who received baseline screening LDCT scans in (with and without SDM)	332
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	402
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	426
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	76
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	82
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	32
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	46
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	19
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	28
Follow-up Rate %	68
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1503

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	406
Total number of people screened in	406
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	168
Total number of people who received baseline screening LDCT scans in (with and without SDM)	168
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	203
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	215
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	38
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	41
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	16
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	23
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	10
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	14
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1983

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	303
Total number of people screened in	303
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	120
Total number of people who received baseline screening LDCT scans in (with and without SDM)	120
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	145
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	154
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	27
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	29
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	12
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	17
Follow-up Rate %	71
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	7
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	10
Follow-up Rate %	70
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1231

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	504
Total number of people screened in	504
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	251
Total number of people who received baseline screening LDCT scans in (with and without SDM)	251
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	304
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	322
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	57
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	62
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	24
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	35
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	15
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	21
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1502

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	254
Total number of people screened in	254
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	80
Total number of people who received baseline screening LDCT scans in (with and without SDM)	80
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	97
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	103
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	18
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	19
Follow-up Rate %	95
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	8
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	11
Follow-up Rate %	73
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	5
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	7
Follow-up Rate %	71
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1501

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	737
Total number of people screened in	737
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	362
Total number of people who received baseline screening LDCT scans in (with and without SDM)	362
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	438
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	464
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	83
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	90
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	35
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	51
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	21
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	30
Follow-up Rate %	70
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1980

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	840
Total number of people screened in	840
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	333
Total number of people who received baseline screening LDCT scans in (with and without SDM)	333
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	403
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	427
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	76
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	82
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	32
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	46
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	19
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	28
Follow-up Rate %	68
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1500

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	660
Total number of people screened in	660
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	262
Total number of people who received baseline screening LDCT scans in (with and without SDM)	262
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	317
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	336
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	60
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	65
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	25
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	36
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	15
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	22
Follow-up Rate %	68
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1234

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	745
Total number of people screened in	745
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	295
Total number of people who received baseline screening LDCT scans in (with and without SDM)	295
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	357
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	378
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	67
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	72
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	29
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	42
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	17
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	25
Follow-up Rate %	68
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1233

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	182
Total number of people screened in	182
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	72
Total number of people who received baseline screening LDCT scans in (with and without SDM)	72
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	87
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	92
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	16
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	17
Follow-up Rate %	94
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	7
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	10
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	4
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	6
Follow-up Rate %	67
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1504

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	991
Total number of people screened in	991
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	393
Total number of people who received baseline screening LDCT scans in (with and without SDM)	393
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	476
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	504
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	90
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	97
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	38
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	55
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	23
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	33
Follow-up Rate %	70
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1505

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	134
Total number of people screened in	134
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	53
Total number of people who received baseline screening LDCT scans in (with and without SDM)	53
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	64
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	68
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	12
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	13
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	5
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	7
Follow-up Rate %	71
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	3
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	4
Follow-up Rate %	75
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1499

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	293
Total number of people screened in	293
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	116
Total number of people who received baseline screening LDCT scans in (with and without SDM)	116
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	141
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	149
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	27
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	29
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	11
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	16
Follow-up Rate %	69
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	7
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	10
Follow-up Rate %	70
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1982

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	250
Total number of people screened in	250
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	99
Total number of people who received baseline screening LDCT scans in (with and without SDM)	99
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	120
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	127
Follow-up Rate %	94
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	23
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	25
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	10
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	14
Follow-up Rate %	71
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	6
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	9
Follow-up Rate %	67
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1497

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	258
Total number of people screened in	258
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	102
Total number of people who received baseline screening LDCT scans in (with and without SDM)	102
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	124
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	131
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	23
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	25
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	10
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	14
Follow-up Rate %	71
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	6
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	9
Follow-up Rate %	67
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1498

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	371
Total number of people screened in	371
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	147
Total number of people who received baseline screening LDCT scans in (with and without SDM)	147
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	178
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	188
Follow-up Rate %	95
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	34
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	37
Follow-up Rate %	92
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	14
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	20
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	9
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	13
Follow-up Rate %	69
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Leslie Whalen
Title	UHC Lung Health Program Manager
Email	leslie.whalen@uhhospitals.org
Phone	(216)-406-4641
User ID	Melissa Loop
Facility ID	1978

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	583
Total number of people screened in	583
Screen-eligible Rate	100
Screen by which criteria (select all that apply)	CMS
Total number of people who received baseline screening LDCT scans in where SDM is documented	221
Total number of people who received baseline screening LDCT scans in (with and without SDM)	221
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	441
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	582
Follow-up Rate %	76
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	14
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	15
Follow-up Rate %	93
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	7
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	7
Follow-up Rate %	100
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	6
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	6
Follow-up Rate %	100
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	4
Total nonsurgical lung biopsies in	5
Nonmalignant/Nondiagnostic Biopsy Rate %	80
	Yes
	Yes
Stage I %	0
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	0
Name	Michael D. Ramsaier
Title	Lung Cancer Screening Coordinator
Email	michael.ramsaIer@hmhn.org
Phone	(551)-996-3384
User ID	Michael Ramsaier
Facility ID	1162

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	No
Comments	Most scans coming from Emergency Room/outpatient exams where we cannot control these factors.
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Comments	Implementing AI tracking for IPN management
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	6
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	QURE AI implementation
Institutional tools are engaged to ensure all IPNs are identifed and managed.	No
Name	Meaghan Adkins
Title	Lung Program Nurse Coordinator
Email	madkins@som.umaryland.edu
Phone	(410)-328-5639
User ID	Meaghan Adkins
Facility ID	2216

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	USPSTF criteria
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Chest radiology, IP, pulm, APP, and navigator have weekly nodule meetings to go over concerning findings and recommended next steps
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	Have a fully integrated tobacco treatment clinic within our pulmonary office that is run by physician and APP. Patients are seen by this team for their screening exam appointments as well
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	Tracking occurs within our EMR system and is followed by a navigator to remind and schedule patients
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meaghan Adkins
Title	Lung Program Nurse Coordinator
Email	madkins@som.umaryland.edu
Phone	(410)-328-5639
User ID	Meg Fay Mortman
Facility ID	1824

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cynthia Trocano-Bonnell
Title	Supervisor Medical Imaging Nursing Support
Email	cynthia.trocano-bonnell@stclair.org
Phone	(412)-942-3123
User ID	Cynthia Trocano-Bonnell
Facility ID	2219

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cynthia Trocano-Bonnell
Title	Supervisor Medical Imaging Nursing Support
Email	cynthia.trocano-bonnell@stclair.org
Phone	(412)-942-3123
User ID	Cynthia Trocano-Bonnell
Facility ID	2218

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Namita Puran
Title	Nurse Practitioner
Email	namita.puran@medstar.net
Phone	(917)-889-4032
User ID	Namita Puran
Facility ID	1651

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kresta Grabau
Title	RN Nurse Navigator
Email	KGrabau@memorialcare.org
Phone	(714)-378-7650
User ID	Kresta Grabau
Facility ID	2017

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kresta Grabau
Title	RN Nurse Navigator
Email	KGrabau@memorialcare.org
Phone	(714)-378-7650
User ID	Kresta Grabau
Facility ID	2017

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Keith Mortman, MD
Title	Chief, Thoracic Surgery
Email	kmortman@mfa.gwu.edu
Phone	(202)-741-3220
User ID	Keith Mortman
Facility ID	1008

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Keith Mortman, MD
Title	Chief, Thoracic Surgery
Email	kmortman@mfa.gwu.edu
Phone	(202)-741-3220
User ID	Keith Mortman
Facility ID	1008

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	2217

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristin Walsh
Title	Patient Care Coordinator
Email	kristin.jones2@nm.org
Phone	(630)-933-4325
User ID	Kristin Walsh
Facility ID	1884

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristin Walsh
Title	Patient Care Coordinator
Email	kristin.jones2@nm.org
Phone	(630)-933-4325
User ID	Kristin Walsh
Facility ID	1883

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristin Walsh
Title	Patient Care Coordinator
Email	kristin.jones2@nm.org
Phone	(630)-933-4325
User ID	Kristin Walsh
Facility ID	2210

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristin Walsh
Title	Patient Care Coordinator
Email	kristin.jones2@nm.org
Phone	(630)-933-4325
User ID	Kristin Walsh
Facility ID	1174

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristin Walsh
Title	Patient Care Coordinator
Email	kristin.jones2@nm.org
Phone	(630)-933-4325
User ID	Kristin Walsh
Facility ID	1173

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	USPSTF criteria
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Chest radiology, IP, pulm, APP, and navigator have weekly nodule meetings to go over concerning findings and recommended next steps
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	Have a fully integrated tobacco treatment clinic within our pulmonary office that is run by physician and APP. Patients are seen by this team for their screening exam appointments as well
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	Tracking occurs within our EMR system and is followed by a navigator to remind and schedule patients
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meaghan Adkins
Title	Lung Program Nurse Coordinator
Email	madkins@som.umaryland.edu
Phone	(410)-328-5639
User ID	Meaghan Adkins
Facility ID	2216

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kersten Smith
Title	CT Lung Screening Patient Coordinator
Email	kersten.smith@nm.org
Phone	(708)-923-8881
User ID	Kersten Smith
Facility ID	2213

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kersten Smith
Title	CT Lung Screening Patient Coordinator
Email	kersten.smith@nm.org
Phone	(708)-923-8881
User ID	Kersten Smith
Facility ID	2214

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kersten Smith
Title	CT Lung Screening Patient Coordinator
Email	kersten.smith@nm.org
Phone	(708)-923-8881
User ID	Kersten Smith
Facility ID	2215

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2211

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Emily Phillips
Title	CT Lung Screening Patient Care Coordinator
Email	Emily.Phillips@nm.org
Phone	(815)-759-4262
User ID	Emily Phillips
Facility ID	1820

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Emily Phillips
Title	CT Lung Screening Patient Care Coordinator
Email	Emily.Phillips@nm.org
Phone	(815)-759-4262
User ID	Emily Phillips
Facility ID	1083

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Emily Phillips
Title	CT Lung Screening Patient Care Coordinator
Email	Emily.Phillips@nm.org
Phone	(815)-759-4262
User ID	Emily Phillips
Facility ID	1419

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Emily Phillips
Title	CT Lung Screening Patient Care Coordinator
Email	Emily.Phillips@nm.org
Phone	(815)-759-4262
User ID	Emily Phillips
Facility ID	1818

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	No
Comments	We are working on this.
Institutional tools are engaged to ensure all IPNs are identifed and managed.	No
Comments	We are working on this.
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2208

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	No
Comments	We are working on this.
Institutional tools are engaged to ensure all IPNs are identifed and managed.	No
Comments	We are working on this.
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2209

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	268
Total number of people screened in	270
Screen-eligible Rate	99
Screen by which criteria (select all that apply)	CMS, NCCN, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	76
Total number of people who received baseline screening LDCT scans in (with and without SDM)	81
SDM Documentation Rate	94
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	190
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	267
Follow-up Rate %	71
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	14
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	20
Follow-up Rate %	70
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	11
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	11
Follow-up Rate %	100
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	3
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	3
Follow-up Rate %	100
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	1
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	1
Total nonsurgical lung biopsies in	1
Nonmalignant/Nondiagnostic Biopsy Rate %	100
	No
	No
Stage I	1
Stage I %	100
Stage II %	0
Stage III %	0
Stage IV %	0
Total screen-detected lung cancers	1
Name	Sherri Hoag
Title	Nurse Navigator
Email	SHoag@memorialcare.org
Phone	(714)-787-6938
User ID	Sheri Hoag
Facility ID	1199

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristine Collinson
Title	Quality Coordinator
Email	kcollinson@pennstatehealth.psu.edu
Phone	(610)-378-2286
User ID	Matthew Coffroth
Facility ID	1172

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	877
Total number of people screened in	914
Screen-eligible Rate	96
Screen by which criteria (select all that apply)	CMS, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	452
Total number of people who received baseline screening LDCT scans in (with and without SDM)	452
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	857
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	964
Follow-up Rate %	89
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	35
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	45
Follow-up Rate %	78
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	28
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	29
Follow-up Rate %	97
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	22
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	22
Follow-up Rate %	100
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I	16
Stage II	3
Stage III	7
Stage IV	3
Stage I %	55
Stage II %	10
Stage III %	24
Stage IV %	10
Total screen-detected lung cancers	29
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	1724

Total number of people screened in who meet CMS, NCCN, USPSTF criteria	723
Total number of people screened in	758
Screen-eligible Rate	95
Screen by which criteria (select all that apply)	CMS, USPSTF
Total number of people who received baseline screening LDCT scans in where SDM is documented	397
Total number of people who received baseline screening LDCT scans in (with and without SDM)	397
SDM Documentation Rate	100
All CPT 71271 LDCT lung cancer screening exams in utilized low dose protocols with the dose index volume (CTDIvol) noted in the exam report, and a CTDIvol of 3mGy or less for a standard-sized patient (with lower or higher CTDIvol for smaller or larger patients), per ACR Practice Parameters.	Yes
All radiologists participating in reading 71271 LDCT lung cancer screening exams in utilized LungRADS to report exam results.	Yes
Consult with or refer to a Nodule Review Board or Multidisciplinary Team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
	Yes
	Yes
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s) who completed this exam	712
Total number of people due for repeat annual LDCT screening in based on prior category Lung-RADS® 1 or 2 finding(s)	821
Follow-up Rate %	87
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< one year) follow-up scan in who completed it	34
Total number of people with category Lung-RADS® 3 finding(s) due for an interval (< 1 year) follow-up scan in	42
Follow-up Rate %	81
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in who completed it	28
Total number of people with category Lung-RADS® 4A finding(s) due for an interval (< 1 year) scan or diagnostic study or intervention* in	29
Follow-up Rate %	97
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for an interval scan or diagnostic intervention/study* in who completed it	9
Total number of people with category Lung-RADS® 4B or 4X finding(s) due for interval (< 1 year) scan or diagnostic intervention/study* in	10
Follow-up Rate %	90
Surgical lung resections with benign (nonmalignant) pathology in	0
Total surgical lung resections in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in	0
Total nonsurgical lung biopsies in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
	Yes
	Yes
Stage I	16
Stage II	3
Stage III	7
Stage IV	3
Stage I %	55
Stage II %	10
Stage III %	24
Stage IV %	10
Total screen-detected lung cancers	29
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	1723

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2209

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2208

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	We do not have a thoracic surgeon on staff, but we refer patients out to thoracic surgery as needed and as per NCCN guidelines.
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	*See above
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2209

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	We do not have a thoracic surgeon on staff, but we refer patients out to thoracic surgery as needed and as per NCCN guidelines.
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	*See above
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2208

Nodule Reporting	Yes
Nodule Review Board / MDT	Yes
Communication Process	Yes
Cessation Support	Yes
Total number of patients with incidental pulmonary nodule(s) who received follow-up imaging by LDCT protocol (radiation dose is < 3 mGy CTDIvol for individuals with below normal or normal BMI) in	0
Total patients with incidental pulmonary nodule(s) completing follow-up CT imaging in	77
LDCT Protocol Compliance Rate %	0
Comments	Patient may have had LDCT performed but it was not ordered this way making tracking more difficult. The order for this is used for LCS normally
Tracking Adherence	Yes
Select all that apply	Tracking software, EHR appointment recall system
Outcomes Review	Yes
Select all that apply	Internal quality outcomes data and metrics capturing policies and procedures, Established internal quality dashboard, Internal quality outcomes metrics, reporting policies and procedures
Surgical lung resections with benign (nonmalignant) pathology in patients with IPN in	0
Total surgical lung resections in patients with IPN in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in patients with IPN in	0
Total nonsurgical lung biopsies in patients with IPN in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
Score	6
Qualification Status	Qualified
Institutional Workflows	Yes
Institutional Tools	Yes
Select all that apply	Natural Language Processing program, Identification of IPNs on imaging by AI
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	1723

Nodule Reporting	Yes
Nodule Review Board / MDT	Yes
Communication Process	Yes
Cessation Support	Yes
Total number of patients with incidental pulmonary nodule(s) who received follow-up imaging by LDCT protocol (radiation dose is < 3 mGy CTDIvol for individuals with below normal or normal BMI) in	0
Total patients with incidental pulmonary nodule(s) completing follow-up CT imaging in	77
LDCT Protocol Compliance Rate %	0
Comments	Pt's with incidental findings did not have CT order for LDCT even though they may have received lower does this is not easily trackable.
Tracking Adherence	Yes
Select all that apply	Tracking software, EHR appointment recall system
Outcomes Review	Yes
Select all that apply	Internal quality outcomes data and metrics capturing policies and procedures, Established internal quality dashboard, Internal quality outcomes metrics, reporting policies and procedures
Surgical lung resections with benign (nonmalignant) pathology in patients with IPN in	0
Total surgical lung resections in patients with IPN in (excluding therapeutic resections where malignancy diagnosed pre-surgery)	0
Nonmalignant Resection Rate %	0
Nonsurgical lung biopsies with benign or nondiagnostic pathology results in patients with IPN in	0
Total nonsurgical lung biopsies in patients with IPN in	0
Nonmalignant/Nondiagnostic Biopsy Rate %	0
Comments	Procedures are not performed at this facility
Score	6
Qualification Status	Qualified
Institutional Workflows	Yes
Institutional Tools	Yes
Select all that apply	Natural Language Processing program, Identification of IPNs on imaging by AI
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	1724

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Minnie
Title	Mouse
User ID	Meg Fay Mortman
Facility ID	1998

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2207

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	We do not have a thoracic surgeon on site, but refer out to thoracic surgery per NCCN Guidelines
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	We do not have a thoracic surgeon on site (see above).
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2207

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Diana Feller
Title	Outpatient Pulmonology Administrator
Email	diana.feller@hillcrest.com
Phone	(918)-382-2560
User ID	Mandy Damon
Facility ID	2206

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Alex Foley
Title	Outpatient Oncology Administrator
Email	alexander.foley@hillcrest.com
Phone	(918)-579-7096
User ID	Mandy Damon
Facility ID	2206

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Emily Donaldson
Title	Incidental Lung Nodule Nurse Navigator
Email	emily.donaldson@hillcrest.com
Phone	(918)-724-6752
User ID	Mandy Damon
Facility ID	2206

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kristen Cross
Title	Lung Screening Nurse Navigator
Email	kristen.cross@hillcrest.com
Phone	(918)-579-5864
User ID	Mandy Damon
Facility ID	2206

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	2193

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	2192

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	2190

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Megan Stickell
Title	Navigator
Email	mstickell@wkhs.com
Phone	(318)-212-8455
User ID	Megan Stickell
Facility ID	2191

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1488

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1482

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1485

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1487

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1486

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1484

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1481

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1483

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1479

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	1097

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2204

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2205

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2200

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2203

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2202

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2198

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2201

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2199

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2197

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Anderson
Title	RTR(R)(CT)
Email	andersonal6@upmc.edu
Phone	(717)-533-1736
User ID	AMY ANDERSON
Facility ID	2196

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	Shared decision counseling
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Comments	ACR Accredited
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	Lung-RADS
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Grady Reicker
Title	Chief CT Technologist
Email	greicker@pennstatehealth.psu.edu
Phone	(223)-287-7252
User ID	Grady Reicker
Facility ID	2195

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1791

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2173

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	No
Comments	Hunterdon does not have a thoracic surgeon on staff. However, we refer patients to external thoracic surgeons for evaluation and consideration of surgical management.
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	9
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	As mentioned above, Hunterdon does not have a thoracic surgeon on staff.
Name	Samantha Geiger
Title	Nurse Navigator
Email	SGEIGER@HHSNJ.ORG
Phone	(908)-237-7079
User ID	Samantha Geiger
Facility ID	2173

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1445

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1447

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1446

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	No
Comments	No tumor board in this outpatient setting.
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	Information is provided to patients.
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	No
Comments	No specific process for this.
Calculated Section Total	7
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Lynn Bell
Title	RN and LCR Navigator
Email	bell3@upmc.edu
Phone	(412)-650-2963
User ID	David Rimsek
Facility ID	1845

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Andrea Covey
Title	MD
Email	andrea.covey@va.gov
Phone	(816)-861-4700
User ID	Kristen Williams
Facility ID	1844

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2184

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2186

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2187

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2181

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	Manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2188

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	Manager lung screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2183

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	Manager Lung Screening program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2182

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghan McHugh
Title	Manager Lung Screening Program
Email	meghan.mchugh@aah.org
Phone	(920)-461-4043
User ID	Meghan McHugh
Facility ID	2185

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Yaron Perry
Title	Chief Division of Thoracic Surgery
Email	yperry@buffalo.edu
Phone	(912)-414-7273
User ID	Yaron Perry
Facility ID	1934

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	Verify pack year and age. Our team has an IRB approved clinical trial open for accrual for those between the ages of 40-49 with a 20-pack year smoking history.
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Darcy Doege
Title	RN Clinical Supervisor
Email	darcy.doege@advocatehealth.org
Phone	(913)-424-6431
User ID	Darcy Doege
Facility ID	1557

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Katherine Jacobson
Title	Practice Manager
Email	katherine@pulmpro.com
Phone	(818)-282-3667
User ID	Katherine Jacobson
Facility ID	2180

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Katherine Jacobson
Title	Practice Manager
Email	katherine@pulmpro.com
Phone	(818)-282-3667
User ID	Katherine Jacobson
Facility ID	2180

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Comments	Utilizing Fleischner Society Criteria on radiology reports
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Comments	Any incidental nodule either suspicious appearing 8mm are discussed during a bi-weekly Pulmonary Multidisciplinary Conference attending by interventional pulmonology, radiology, and thoracic surgery
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Comments	All patients are called for any detected nodules for follow up imaging or referral for biopsy, notes are written in VA EHR with primary care provider attached to the note with plan and documentation of communication
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Comments	Current smoking status always asked with advisement to quit, facility is currently revamping Tobacco Cessation program with plans for referral once re-established.
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Comments	Radiology service is very active in lung cancer screening and now incidental nodules; utilize low dose CT scans dedicated to incidental nodules (outside of LCS designation), with high dose CT scans utilized for Ion Robotic bronchoscopy planning
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Comments	Tracking is currently performed within VA CCTS program. Looking into purchasing Optellum in the future for tracking
Internal clinical outcomes review and quality improvement process.	Yes
Comments	QI performed on a monthly basis with direct reporting to facility chief of staff on a quarterly basis
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	All incidental nodules on various types of imaging studies are flagged by radiology and automatically detected by our Clinical Surveillance Unit (CSU) Incidental Nodule coordinator. Primary care, specialiteis and inpatient teams can also refer for consultation/tracking directly to CSU coordinator
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Comments	Utilizing "flagging codes" by Radiology
Name	Alison Larson
Title	CSU Incidental Nodule coordinator
Email	Alison.Larson1@va.gov
Phone	(505)-265-1711
User ID	Arjan Flora
Facility ID	2019

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Joel Helmke
Title	CEO, Knight Cancer Institute
Email	lungcancer@ohsu.edu
Phone	(503)-494-8311
User ID	Chara Rydzak
Facility ID	1957

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Joel Helmke
Title	CEO, Knight Cancer Institute
Email	lungcancer@ohsu.edu
Phone	(503)-494-8311
User ID	Chara Rydzak
Facility ID	1957

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	We offer a peer reviewed internal cessation program available to all patients and employees. This started as a Moonshot grant funded program.
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Teeples
Title	Director of Clinical Business Planning and Cancer Registry
Email	teeples@ohsu.edu
Phone	(503)-453-7578
User ID	Chara Rydzak
Facility ID	1957

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	We have a partnership with an outside facility to refer for surgical intervention if needed.
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Name	Katelyn Grados
Title	Lung Screening Program Coordinator
Email	kmg0322@mountnittany.org
Phone	(814)-231-6881
User ID	Katelyn Grados
Facility ID	1559

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Michael Mair
Title	RN
Email	michael.mair@commonspirit.org
Phone	(916)-962-8864
User ID	Michael Mair
Facility ID	2178

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Michael Mair
Title	RN
Email	michael.mair@commonspirit.org
Phone	(916)-962-8864
User ID	Michael Mair
Facility ID	2177

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Michael Mair
Title	RN
Email	michael.mair@commonspirit.org
Phone	(916)-962-8864
User ID	Michael Mair
Facility ID	2176

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Michael Mair
Title	RN
Email	michael.mair@commonspirit.org
Phone	(916)-962-8864
User ID	Michael Mair
Facility ID	2175

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Michael Mair
Title	RN
Email	michael.mair@commonspirit.org
Phone	(916)-962-8864
User ID	Michael Mair
Facility ID	2174

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	No
Comments	Incidental only come from AI dashboard.
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Melissa Jane Clark
Title	RN Lung Program Coordinator
Email	melissa.jane.clark@adventhealth.com
Phone	(863)-386-6475
User ID	melissa Clark
Facility ID	1912

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sydney
Title	CT LUNG NAVIGATOR
Email	gilmansm2@upmc.edu
Phone	(724)-250-4594
User ID	SYDNEY GILMAN
Facility ID	1766

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sydney
Title	CT LUNG NAVIGATOR
Email	gilmansm2@upmc.edu
Phone	(724)-250-4594
User ID	SYDNEY GILMAN
Facility ID	1775

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sydney
Title	CT LUNG NAVIGATOR
Email	gilmansm2@upmc.edu
Phone	(724)-250-4594
User ID	SYDNEY GILMAN
Facility ID	1765

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1790

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1790

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kori Pitt
Title	Oncology Program Manager
Email	kori.pitt@renown.org
Phone	(775)-982-6035
User ID	Kori Pitt
Facility ID	1790

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Amy Williams
Title	Oncology Program Leader
Email	Amy.Williams13@hcahealthcare.com
Phone	(941)-792-6236
User ID	Amy Willams
Facility ID	1881

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Comments	We have an incidental lung nodule program managed by Care Assure.
Name	Amy Williams
Title	Oncology Program Leader
Email	Amy.Williams13@hcahealthcare.com
Phone	(941)-792-6236
User ID	Amy Willams
Facility ID	1881

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Amy Williams
Title	Oncology Program Leader
Email	Amy.Williams13@hcahealthcare.com
Phone	(941)-792-6236
User ID	Amy Willams
Facility ID	1881

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Williams
Title	Oncology Program Leader
Email	Amy.Williams13@hcahealthcare.com
Phone	(941)-792-6236
User ID	Amy Willams
Facility ID	1881

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Andrea Potter
Title	Thoracic Nurse Navigator
Email	Andrea.potter@providence.org
Phone	(425)-390-4658
User ID	Andrea Potter
Facility ID	1517

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	WE ALSO HAVE A SELF-PAY PROGRAM THAT SCREENS HIGH-RISK PATIENTS FOR $171.00
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	We currently use the NH QuitNow line.
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Fatima Rocco
Title	Lung Cancer Screening Program Coordinator
Email	frocco@elliot-hs.org
Phone	(603)-663-1833
User ID	Fatima Rocco
Facility ID	1849

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	WE ALSO HAVE A SELF-PAY PROGRAM THAT SCREENS HIGH-RISK PATIENTS FOR $171.00
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	WE CURRENTLY USE THE NH QUITNOW
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Fatima Rocco
Title	Lung Ca
Email	frocco@elliot-hs.org
Phone	(603)-663-1833
User ID	Fatima Rocco
Facility ID	1848

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	2169

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	2169

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	2169

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	2169

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1958

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1958

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1394

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1394

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1395

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1395

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1396

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1396

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1397

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Comments	weekly
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Comments	Registry
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	Vizio
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Comments	AI natural language tracker
Name	Sandra Jennings
Title	Director of Oncology Support Services
Email	sandra.jennings@adventhealth.com
Phone	(386)-231-4032
User ID	sandra Jennings
Facility ID	1397

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	1472

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2157

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2163

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2165

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2168

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2160

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2162

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2158

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2159

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2161

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2167

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2166

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Cassie Carroll Frazier
Title	Nurse Practitioner
Email	fraziercc@musc.edu
Phone	(843)-792-2309
User ID	Cassie Frazier
Facility ID	2164

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Duremelle Deutou
Title	FNP
Email	duremelle.deutou@nychhc.org
Phone	(718)-579-4946
User ID	Duremelle Deutou
Facility ID	2155

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1690

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1689

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1687

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1687

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1687

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Laura Eatmon
Title	Lung Health Nurse Navigator
Email	laura.eatmon@adventhealth.com
Phone	(352)-690-5675
User ID	Laura Eatmon
Facility ID	1687

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Marly Roberson
Title	Martin O'Neil Cancer Center Manager
Email	robersm@ah.org
Phone	(707)-967-5752
User ID	Marcia Lynn Beauchamp
Facility ID	1911

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Marcia Lynn Beauchamp
Title	clerical associate; cancer services
Email	beauchml@ah.org
Phone	(707)-967-5812
User ID	Marcia Lynn Beauchamp
Facility ID	1911

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Arpan Patel
Title	Associate Professor, Chief Quality Officer for Wilmot
Email	Arpan_Patel@URMC.Rochester.edu
Phone	(315)-525-2102
User ID	Arpan Patel
Facility ID	2153

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	No
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Kelly M Frontino
Title	Manager
Email	Kelly.Frontino@stjoe.org
Phone	(714)-771-8082
User ID	Kelly Frontino
Facility ID	1104

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kelly M Frontino
Title	Manager
Email	Kelly.Frontino@stjoe.org
Phone	(714)-771-8082
User ID	Kelly Frontino
Facility ID	1104

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kelly M Frontino
Title	Manager
Email	Kelly.Frontino@stjoe.org
Phone	(714)-771-8082
User ID	Kelly Frontino
Facility ID	1104

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1313

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Deborah Jeskey
Title	Lung/GU Oncology Program Coordinator
Email	Deborah.jeskey@northside.com
Phone	(678)-313-1230
User ID	Deb Jeskey
Facility ID	1925

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Deborah Jeskey
Title	Lung/GU Oncology Program Coordinator
Email	Deborah.jeskey@northside.com
Phone	(678)-313-1230
User ID	Deb Jeskey
Facility ID	1924

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Deborah Jeskey
Title	Lung/GU Oncology Program Coordinator
Email	Deborah.jeskey@northside.com
Phone	(678)-313-1230
User ID	Deb Jeskey
Facility ID	1923

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Deb Jeskey
Title	Lung /GU Oncology Program Coordinator
Email	Deborah.jeskey@northside.com
Phone	(678)-313-1230
User ID	Deb Jeskey
Facility ID	1926

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2152

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	Sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2152

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2152

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2152

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2151

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	Sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2151

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2151

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	2151

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1322

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	Sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1322

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1322

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1322

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1323

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	Sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1323

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1323

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1323

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1324

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	Sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1324

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1324

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Sandra Murray
Title	Nurse Navigator
Email	sandra.murray@jefferson.edu
Phone	(856)-557-5322
User ID	Sandy Murray
Facility ID	1324

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Crystal Terry
Title	Lung Clinic Manager
Email	crystal.terry@advocatehealth.org
Phone	(706)-509-5021
User ID	Lisa Acree
Facility ID	2150

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amanda Pepple
Title	Director
Email	amanda.pepple@trinity-health.org
Phone	(734)-748-3220
User ID	Amanda Pepple
Facility ID	1242

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amanda Pepple
Title	Director
Email	amanda.pepple@trinity-health.org
Phone	(734)-748-3220
User ID	Amanda Pepple
Facility ID	1474

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2149

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2148

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2147

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2146

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2145

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2144

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2143

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2142

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2141

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	1327

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2140

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2139

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2138

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2137

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	2136

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Lamb
Title	Lung Cancer Screening Navigator
Email	jessica.lamb@prismahealth.org
Phone	(864)-454-4269
User ID	Jessica Lamb
Facility ID	1326

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Jessica Poetzsch
Title	Quality and Accreditation Manager
Email	jessica.poetzsch@midhosp.org
Phone	(860)-358-2066
User ID	Jessica Poetzsch
Facility ID	1041

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Wendy Daniel Firestone, BSN, RN, OCN
Title	Nurse Navigator
Email	wendy.firestone@erlanger.org
Phone	(423)-778-7460
User ID	Wendy Firestone
Facility ID	1914

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Wendy Daniel Firestone, BSN, RN, OCN
Title	Nurse Navigator
Email	wendy.firestone@erlanger.org
Phone	(423)-778-7460
User ID	Wendy Firestone
Facility ID	1914

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	David Tom Cooke, MD, FACS, MAMSE
Title	Physician in Chief, UC Davis Comprehensive Cancer Center
Email	dtcooke@health.ucdavis.edu
Phone	(916)-734-3861
User ID	David Cooke
Facility ID	1170

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	David Tom Cooke, MD, FACS, MAMSE
Title	Physician in Chief, UC Davis Comprehensive Cancer Center
Email	dtcooke@health.ucdavis.edu
Phone	(916)-734-3861
User ID	David Cooke
Facility ID	1170

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	David Tom Cooke, MD, FACS, MAMSE
Title	Physician in Chief, UC Davis Comprehensive Cancer Center
Email	dtcooke@health.ucdavis.edu
Phone	(916)-734-3861
User ID	David Cooke
Facility ID	1170

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	David Tom Cooke, MD, FACS, MAMSE
Title	Physician in Chief, UC Davis Comprehensive Cancer Center
Email	dtcooke@health.ucdavis.edu
Phone	(916)-734-3861
User ID	David Cooke
Facility ID	1170

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1371

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1370

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	2038

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	2030

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1369

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1713

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Debra Knight
Title	BSN, RN
Email	dknight@phoebehealth.com
Phone	(229)-312-5757
User ID	Debra Knight
Facility ID	1492

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Debra Knight
Title	BSN, RN, Lung Navigator
Email	dknight@phoebehealth.com
Phone	(229)-312-5757
User ID	Debra Knight
Facility ID	1198

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lenia Batas
Title	Cancer Screening Program manager
Email	lbatas@maimo.org
Phone	(929)-627-0274
User ID	Lenia Batas
Facility ID	1100

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Dr. Vishal Vashistha
Title	Medical Director
Email	VVashistha@maimo.org
Phone	(718)-765-2682
User ID	Lenia Batas
Facility ID	1100

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2130

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2118

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2126

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2124

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2125

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2132

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2131

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2133

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Meghann Roberts
Title	Director of imaging
Email	mroberts@windsongwny.com
Phone	(716)-276-0376
User ID	Meghann Roberts
Facility ID	1343

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Rachael Schmidt
Title	Program Director
Email	raschmidt@nebraskamed.com
Phone	(402)-559-1889
User ID	Rachael Schmidt
Facility ID	2129

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Dr. Cynthia Chin
Title	Thoracic Surgeon
Email	creilly@wphospital.org
Phone	(914)-849-7299
User ID	Catherine Reilly
Facility ID	1063

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brooke Ruane
Title	Nurse Practitioner
Email	brooke.ruane@jefferson.edu
Phone	(215)-503-0198
User ID	Brooke Ruane
Facility ID	1594

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brooke Ruane
Title	Nurse Practitioner
Email	brooke.ruane@jefferson.edu
Phone	(215)-503-0198
User ID	Brooke Ruane
Facility ID	1594

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brooke Ruane
Title	Nurse Practitioner
Email	brooke.ruane@jefferson.edu
Phone	(215)-503-0198
User ID	Brooke Ruane
Facility ID	1594

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brooke Ruane
Title	Nurse Practitioner
Email	brooke.ruane@jefferson.edu
Phone	(215)-503-0198
User ID	Brooke Ruane
Facility ID	1594

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Samantha D'Annunzio
Title	MD
Email	sdannunzio@westmedgroup.com
Phone	(914)-848-8888
User ID	Elizabeth Albanese
Facility ID	1866

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Ittersagen
Title	Nurse Navigator
Email	Anorwich@Silvercross.org
Phone	(815)-300-5853
User ID	Amy Ittersagen
Facility ID	2127

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Claudia Henschke
Title	Professor of Radiology
Email	Claudia.Henschke@mountsinai.org
Phone	(212)-241-2768
User ID	Patricia Costello
Facility ID	1113

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amanda Pepple
Title	Director
Email	amanda.pepple@trinity-health.org
Phone	(734)-748-3220
User ID	Amanda Pepple
Facility ID	1475

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amanda Pepple
Title	Director
Email	amanda.pepple@trinity-health.org
Phone	(734)-748-3220
User ID	Amanda Pepple
Facility ID	1477

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amanda Pepple
Title	Director
Email	amanda.pepple@trinity-health.org
Phone	(734)-748-3220
User ID	Amanda Pepple
Facility ID	1225

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2123

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	No
Comments	Currently working on a process to allow Emergency and Inpatient physicians the ability to refer to nodule clinic prior to patient discharge. Referrals currently come from the patients PCP.
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Comments	The use of AI identifies all incidental nodules and sends them to navigator to manage.
Name	Amber Perez
Title	Supervisor Respiratory Therapy, Lung Disease Navigator
Email	amber.perez@imail.org
Phone	(303)-265-2939
User ID	Amber Perez
Facility ID	1319

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary S. McMullen
Title	Nurse Practitioner
Email	mary.mcmullen@jefferson.edu
Phone	(215)-395-8155
User ID	Marta Poznanska
Facility ID	1219

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Rikki Landers
Title	Manager Oncology Services
Email	Rikki.Landers@imail.org
Phone	(720)-301-7846
User ID	Catherine Bieker
Facility ID	1780

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Shana Bolliger
Title	Director Oncology Services
Email	Shana.Bolliger@imail.org
Phone	(303)-689-6256
User ID	Catherine Bieker
Facility ID	1783

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Autumn Clark
Title	Director Oncology Services
Email	Autumn.Clark@imail.org
Phone	(970)-298-2464
User ID	Catherine Bieker
Facility ID	1782

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Autumn Clark
Title	Director Oncology Services
Email	Autumn.Clark@imail.org
Phone	(970)-298-2464
User ID	Catherine Bieker
Facility ID	1782

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2122

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2121

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	2120

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Megan Gibson
Title	Lung Cancer Screening Navigator
Email	megan.gibson@bjc.org
Phone	(314)-203-5552
User ID	Megan Gibson
Facility ID	1563

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Comments	we have a weekly Pulmonary Nodule clinic that we all meet to discuss these findings and next steps
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Comments	we have an encounter for md's to refer to the nodule clinic and we enter notes in their charts with our recommendations and md is aware of next steps
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Comments	the ordering MD"s are the ones required to discuss with patient's prior to ordering , but when they see a specialists they do discuss importance of cessation
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	we have an actionable findings category and radiologist will send to clinic when they see it on imaging
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Joan Macallister
Title	Oncology Nurse Navigator
Email	jmmacallister@capecodhealth.org
Phone	(508)-862-7661
User ID	Christine Gould
Facility ID	1748

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	we review the orders before scheduling for their eligibility requirements to make sure they meet them
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	ordering providers sign an order that states by signing this order you are confirming patient has received shared decision making and importance of cessation and continuing in the program
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	we use the lung rads scoring system. Fleischner's Guidelines
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	we have a meeting weekly with the program coordinator, radiologist, Oncology nurse navigator, Thoracic surgeon and interventional pulmonologist
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Comments	we have created a visit type of Pulmonary nodule clinic review and once we discuss and come up with a recommendation it gets noted in the chart as an encounter and MD is notified of the plan and/or if additional testing or referrals are needed
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	our EMR has system for tracking unresolved follow ups, patients are sent a reminder letter at 30 days, 60 days and 90 days overdue, after 90 notice is sent to pcp.
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	we upload daily to the ACR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Christine Gould
Title	Lung Cancer Screening Program Coordinator
Email	cgould@capecodhealth.org
Phone	(508)-862-5116
User ID	Christine Gould
Facility ID	2119

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	we review the orders before scheduling for their eligibility requirements to make sure they meet them
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	ordering providers sign an order that states by signing this order you are confirming patient has received shared decision making and importance of cessation and continuing in the program
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	we use the lung rads scoring system. Fleischner's Guidelines
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	we have a meeting weekly with the program coordinator, radiologist, Oncology nurse navigator, Thoracic surgeon and interventional pulmonologist
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Comments	we have created a visit type of Pulmonary nodule clinic review and once we discuss and come up with a recommendation it gets noted in the chart as an encounter and MD is notified of the plan and/or if additional testing or referrals are needed
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	our EMR has system for tracking unresolved follow ups, patients are sent a reminder letter at 30 days, 60 days and 90 days overdue, after 90 notice is sent to pcp.
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	we upload daily to the ACR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Christine Gould
Title	Lung Cancer Screening Program Coordinator
Email	cgould@capecodhealth.org
Phone	(508)-862-5116
User ID	Christine Gould
Facility ID	1748

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1592

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1951

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1950

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1590

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1589

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1588

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1153

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1593

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1054

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Connie Buckley
Title	RN, Lung Screening Navigator
Email	connie.buckley@nortonhealthcare.org
Phone	(502)-636-8327
User ID	Jenny Frantz
Facility ID	1054

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Theresa Maciejewski
Title	Lead RN Patient Navigator
Email	tmmaciejewski@mercy.com
Phone	(513)-624-4500
User ID	Theresa Maciejewski
Facility ID	1306

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Theresa Maciejewski
Title	Lead RN Patient Navigator Mercy Health
Email	tmmaciejewski@mercy.com
Phone	(513)-624-4500
User ID	Theresa Maciejewski
Facility ID	1307

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Theresa Maciejewsi
Title	Lead RN Patient Navigator Mercy Health
Email	tmmaciejewski@mercy.com
Phone	(513)-624-4500
User ID	Theresa Maciejewski
Facility ID	1697

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Ellen Brennan
Title	Lung cancer screening Nurse Navigator
Email	ellen.brennan@bjc.org
Phone	(636)-916-7098
User ID	Ellen Brennan
Facility ID	1562

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2053

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2058

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2059

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2056

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2057

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2055

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1313

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1312

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1311

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1310

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1309

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1308

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1312

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1311

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1310

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1309

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jessica Kerns
Title	Nurse Navigator
Email	jessica.kerns@stelizabeth.com
Phone	(859)-301-4072
User ID	Jessica Kerns
Facility ID	1308

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Comments	unsure
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1371

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Comments	unsure
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1370

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Comments	unsure
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	2038

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Comments	unsure
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	2030

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	No
Comments	Unsure
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	1369

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1441

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1440

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1439

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	we use the USPSTF criteria
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	Will be getting a commerical dashboard that will allow us to pull these reports hopefully within the year. We do not currently have this tracking capability.
Name	Denise Phelps
Title	RN Navigator
Email	denise.phelps@conehealth.com
Phone	(336)-522-8921
User ID	Denise phelps
Facility ID	2033

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1438

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	2115

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	2117

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	2116

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	1213

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	1568

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	1212

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	1211

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Craig Barr
Title	Executive Director
Email	cbarr@hvhs.org
Phone	(724)-773-4578
User ID	Kathleen Osten
Facility ID	1270

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Craig Barr
Title	Executive Director
Email	cbarr@hvhs.org
Phone	(724)-773-4578
User ID	Kathleen Osten
Facility ID	1269

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1437

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1436

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1434

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1433

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator RN
Email	Lisa.Fowlkes@vcuhealth.org
Phone	(804)-627-7939
User ID	Lisa Fowlkes
Facility ID	2114

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator RN
Email	Lisa.Fowlkes@vcuhealth.org
Phone	(804)-628-7939
User ID	Lisa Fowlkes
Facility ID	2110

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator
Email	Lisa.Fowlkes@vcuhealth.org
Phone	(804)-627-7939
User ID	Lisa Fowlkes
Facility ID	2111

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator RN
Email	Lisa.Fowlkes@vcuhealth.org
Phone	(804)-628-7939
User ID	Lisa Fowlkes
Facility ID	2113

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator RN
Email	Lisa.Fowlkes@vcuhealth.org
Phone	(804)-628-7939
User ID	Lisa Fowlkes
Facility ID	2112

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1435

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Elizabeth Campana
Title	Program Manager/ Patient Navigator
Email	elizabeth.s.campana@lahey.org
Phone	(781)-744-7192
User ID	Elizabeth Campana
Facility ID	1075

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Comments	We track positive LCS patients.
Name	Lisa Fowlkes
Title	Lung Cancer Screening Coordinator RN
Email	LIsa.fowlkes@vcuhealth.org
Phone	(804)-628-7939
User ID	Lisa Fowlkes
Facility ID	1060

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Nurse Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1391

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Nurse Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1390

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Nurse Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1389

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Nurse Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1388

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Nurse Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1387

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1386

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendal Delaney
Title	BSN, RN Oncology Navigator
Email	Kendal_Delaney@Mercy.com
Phone	(419)-265-9715
User ID	Kendal Delaney
Facility ID	1385

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jean M Comeau BSN RN
Title	Nurse Navigator
Email	jean.comeau@umassmemorial.org
Phone	(508)-765-3024
User ID	Jean Comeau
Facility ID	2108

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1021

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1028

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Hamm, RN
Title	Lung Nodule Program Coordinator
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1773

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1027

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Hamm, RN
Title	Lung Nodule Program Coordinator
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1771

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1026

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Hamm, RN
Title	Lung Nodule Program Coordinator
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1772

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1023

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Amy Hamm
Title	Lung Nodule Program Coordinator
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1770

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1024

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1022

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Amy Hamm
Title	RN
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1770

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kendra Worden
Title	NP
Email	kworden@mhc.net
Phone	(231)-392-8486
User ID	Kendra Worden
Facility ID	1025

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Amy Hamm
Title	RN
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1770

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Hamm
Title	RN
Email	amy.hamm@hcahealthcare.com
Phone	(727)-619-0436
User ID	Amy Hamm
Facility ID	1770

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Carbo
Title	Project Manager, Lung Cancer Screening
Email	rsd6wu@uvahealth.org
Phone	(410)-533-4590
User ID	Lauren Carbo
Facility ID	1210

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	Patients who do not meet standard criteria but fulfill NCCN group 2 or other high risk criteria such as prolonged occupational exposures / family history etc.,. may obtain their screening via self pay following SDM with the healthcare provider.
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Marquis Demniak, APP
Title	LCSP Coordinator
Email	Marquis.demniak@hsc.wvu.edu
Phone	(304)-598-4882
User ID	Melanie Moccaldi
Facility ID	1112

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Joy Brown
Title	Radiology Quality & Compliance Coordinator
Email	jbrown@limamemorial.org
Phone	(419)-226-5096
User ID	Joy Brown
Facility ID	1220

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Susan Lessar
Title	Vice President, Operations and Oncology Service Line
Email	slessar@valleyhealthlink.com
Phone	(540)-536-1882
User ID	Lindsey Temple
Facility ID	1747

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1351

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2106

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1066

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2107

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1350

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lauren Moore
Title	Thoracic Oncology Program Coordinator
Email	lauren.moore@tidalhealth.org
Phone	(410)-543-7012
User ID	Lauren Moore
Facility ID	2007

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Celeste Titus
Title	Screening Coordinator
Email	titusc@karmanos.org
Phone	(248)-226-2129
User ID	Celeste Titus
Facility ID	1426

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	No
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Comments	nurse navigators follow treatment of patient to make sure they are receiving what recommendations state from LDCT
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Comments	documented on treatment plan
Name	Heather Newcomb
Title	Clinical coordinator
Email	hnewcomb@saratogahospital.org
Phone	(518)-580-2855
User ID	Heather Newcomb
Facility ID	1574

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1351

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2106

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1066

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2107

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1350

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1351

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2106

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1066

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2107

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1350

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2106

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	2107

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1351

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1066

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brandy Dietz
Title	Telehealth Nurse
Email	brandy.dietz@uchealth.com
Phone	(513)-584-0135
User ID	Brandy Waits
Facility ID	1350

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR LCSR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1105

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR LCSR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Brenna Offutt
Title	Nursing Supervisor
Email	Brenna.Milankovich@ahn.org
Phone	(412)-215-8509
User ID	Brenna Milankovich
Facility ID	1430

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jean Comeau BSN RN
Title	Nurse Navigator
Email	jean.comeau@umassmemorial.org
Phone	(508)-765-3024
User ID	Jean Comeau
Facility ID	1626

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stacey Pinckney
Title	Nurse Navigator
Email	stacey.pinckney@umhwest.org
Phone	(616)-252-5220
User ID	Stacey Pinckney
Facility ID	1653

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kelly Horn
Title	Director of Marketing and Community Outreach, Physician Liaison
Email	khorn@nebraskacancer.com
Phone	(531)-329-3655
User ID	Kelly Horn
Facility ID	2090

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	KELLY HORN
Title	Director of Marketing and Community Outreach, Physician Liaison
Email	khorn@nebraskacancer.com
Phone	(531)-329-3655
User ID	Kelly Horn
Facility ID	2090

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy McClary
Title	RN Patient Navigator
Email	amcclary@northernlight.org
Phone	(207)-973-5822
User ID	Amy McClary
Facility ID	1874

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2105

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1945

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1294

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2027

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2028

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1293

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2024

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2025

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2026

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1287

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1137

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	2023

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1281

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1286

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stuart Cohen, MD
Title	Radiologist
Email	SLCohen@northwell.edu
Phone	(516)-562-2819
User ID	Kristina Sopp
Facility ID	1283

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Rodriguez
Title	Registered Nurse
Email	amy.rodriguez2@imail.org
Phone	(303)-403-3611
User ID	Amy Rodriguez
Facility ID	1319

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	The patients will discuss with program provider whom will identify additional risk factors including family history of lung cancer, exposures to radon/asbestos/mold etc, 2nd hand smoking exposures, and past medical history of other cancers.
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	LungRADS
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	At minimum: Clinical program coordinator, Pulmonology, Interventional Pulmonology, and Thoracic Surgery.
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	PenRAD / PenLUNG
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR LCSR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Comments	in process of development
Name	Vita Balista
Title	FNP
Email	vita.balista@wmchealth.org
Phone	(914)-306-0274
User ID	Vita Balista
Facility ID	2104

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Emilia Arndt
Title	Director
Email	emilia.arndt@hcahealthcare.com
Phone	(352)-333-4703
User ID	Emilia Arndt
Facility ID	2103

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jared Ediger
Title	Oncology Navigator
Email	david.ediger@adventhealth.com
Phone	(303)-778-2415
User ID	Jared Ediger
Facility ID	1726

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Rikki Landers
Title	Manager Oncology Services
Email	Rikki.Landers@imail.org
Phone	(720)-301-7846
User ID	Catherine Bieker
Facility ID	1780

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Katie Donnelly
Title	Director Nursing Onc Hospice and Palliative Care
Email	Katie.Donnelly@imail.org
Phone	(406)-233-4029
User ID	Catherine Bieker
Facility ID	1789

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Katie Donnelly
Title	Director Nursing Onc Hospice and Palliative Care
Email	Katie.Donnelly@imail.org
Phone	(406)-233-4029
User ID	Catherine Bieker
Facility ID	1789

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Katie Donnelly
Title	Director Nursing Onc Hospice and Palliative Care
Email	Katie.Donnelly@imail.org
Phone	(406)-233-4029
User ID	Catherine Bieker
Facility ID	1781

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Jerri Doyle
Title	Director Nursing Oncology Service Line
Email	Jerri.Doyle@imail.org
Phone	(406)-723-2840
User ID	Catherine Bieker
Facility ID	1788

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Shana Bolliger
Title	Director Oncology Service Line
Email	Shana.Bolliger@imail.org
Phone	(303)-689-6256
User ID	Catherine Bieker
Facility ID	1783

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Rodriguez
Title	RN Navigator Oncology
Email	Amy.Rodriguez2@imail.org
Phone	(303)-403-3611
User ID	Catherine Bieker
Facility ID	1784

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Casey Bogenschutz
Title	Director Oncology Service Line
Email	Casey.Bogenschutz@imail.org
Phone	(303)-467-8845
User ID	Catherine Bieker
Facility ID	1784

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Sarah Pike
Title	Director Oncology Service Line
Email	Sarah.Pike@imail.org
Phone	(303)-318-3471
User ID	Catherine Bieker
Facility ID	1781

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Comments	CoC & NAPBC accredited
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	No
Comments	CT surgeons on medical staff, but not fellowship trained in thoracic oncology
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	9
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	No fellowship trained Thoracic Oncologist - only board certified CT surgeons
Name	CJ Johnson
Title	Administrative Director - Oncology
Email	cj.johnson@hcahealthcare.com
Phone	(352)-333-5917
User ID	CJ Johnson
Facility ID	2102

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Stephanie L Brown
Title	RN, BSN, Nurse Navigator
Email	stephanie.brown@uchealth.org
Phone	(720)-848-6495
User ID	Stephanie Brown
Facility ID	1399

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Stephanie L Brown
Title	RN, BSN, Nurse Navigator
Email	stephanie.brown@uchealth.org
Phone	(303)-523-1556
User ID	Stephanie Brown
Facility ID	1399

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	done by the referring provider
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	referral to the quit line if indicated
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Marguerite Thomas
Title	cancer center program and accreditation coordinator
Email	Peggy.thomas900@commonspirit.org
Phone	(719)-776-8202
User ID	Peggy Thomas
Facility ID	1384

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	this is done by the referring provider. reinforced if needed by the navigators
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	this is provided by the referring provider through referral to the quit line
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Marguerite Thomas
Title	cancer center program and accreditation coordinator
Email	Peggy.thomas900@commonspirit.org
Phone	(719)-776-8202
User ID	Peggy Thomas
Facility ID	1383

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2093

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2092

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2100

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2091

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2099

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2097

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2096

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2098

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2094

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Mary Jo Evans
Title	Administrator, Imaging Population Health
Email	maryjo_evans@urmc.rochester.edu
Phone	(585)-773-8960
User ID	Mary Jo Evans
Facility ID	2095

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Michelle Heron, RN
Title	Director of Operations
Email	michelle.heron@stjoe.org
Phone	(707)-525-6654
User ID	Kelly Farrow
Facility ID	2011

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kelly Farrow, RN
Title	Registered Nurse
Email	kelly.farrow@stjoe.org
Phone	(707)-525-6648
User ID	Kelly Farrow
Facility ID	2011

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Kathryn Campuzano
Title	Thoracic Oncology/Screening Nurse Navigator
Email	KCampuzano@memorialcare.org
Phone	(156)-248-0774
User ID	KATHRYN CAMPUZANO
Facility ID	2089

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	Surgeon is board certified cardio thoracic attends tumor boards but does not have an office in our cancer center
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	surgeon is cardio-thoracic board certified
Name	Kathryn Campuzano
Title	Thoracic Oncology/Screening Nurse Navigator
Email	KCampuzano@memorialcare.org
Phone	(156)-248-0774
User ID	KATHRYN CAMPUZANO
Facility ID	2089

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Kitty Campuzano
Title	Thoracic Oncology/Screening Nurse Navigator
Email	kathryn.mhc@gmail.com
Phone	(562)-235-0638
User ID	KATHRYN CAMPUZANO
Facility ID	2089

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2087

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2086

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2085

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2084

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2083

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2081

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2081

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2082

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	2082

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1543

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1543

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1542

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1542

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1194

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell, BS RTR.M.CT
Title	Program Manager Lung Screening and Incidentals
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1194

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tia Cantrell
Title	Program Manager
Email	tia.cantrell@advocatehealth.org
Phone	(828)-455-0107
User ID	Tia cantrell
Facility ID	1544

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Cornelison
Title	Advanced Imaging Manager
Email	Amy.Cornelison@coxhealth.com
Phone	(417)-269-1233
User ID	Kim McMillian
Facility ID	1750

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Cornelison
Title	Advanced Imaging Manager
Email	Amy.Cornelison@coxhealth.com
Phone	(417)-269-1233
User ID	Kim McMillian
Facility ID	2061

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amy Cornelison
Title	Advanced Imaging Manager
Email	Amy.Cornelison@coxhealth.com
Phone	(417)-269-1233
User ID	Kim McMillian
Facility ID	2062

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Sherri Hoag
Title	Lung Cancer Nurse Navigator
Email	shoag@memorialcare.org
Phone	(949)-452-7416
User ID	Sheri Hoag
Facility ID	1199

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Liliana Parra
Title	Director Lung Health Institute
Email	liliana.parra@adventhealth.com
Phone	(321)-276-9696
User ID	Lili Parra
Facility ID	1935

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Dr Jennifer Crow
Title	Pathologist
Email	Jennifer.crow@adventhealth.com
Phone	(682)-317-8173
User ID	Lynnette Roberts
Facility ID	2078

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Comments	Structured Incidental Lung Nodule program in place
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	ILN Program in place
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Kristy Robinson
Title	Oncology Clinical Coordinator
Email	kristy.robinson.aprn@adventhealth.com
Phone	(817)-551-5312
User ID	Lynnette Roberts
Facility ID	2078

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Comments	On site oncology APRN, navigator and Oncology Center
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kristy Robinson
Title	Clinical Oncology Coordinator
Email	Kristy.robinson.aprn@adventhealth.com
Phone	(817)-551-5312
User ID	Lynnette Roberts
Facility ID	2078

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Biweekly Tumor Board meeting
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Comments	Tumor Board
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Lynnette Roberts
Title	Director Outpatient Surgery, Endoscopy, Bronchoscopy
Email	lynnette.roberts@adventhealth.com
Phone	(817)-551-2459
User ID	Lynnette Roberts
Facility ID	2078

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	ACR LCSR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Dr. Ben Wandkte
Title	MD, MS
Email	Ben_Wandtke@urmc.rochester.edu
Phone	(585)-396-6633
User ID	Mary Jo Evans
Facility ID	2079

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Jennifer Kummerfeldt
Title	Director of Population Health
Email	jkummerfeldt@masongeneral.com
Phone	(360)-426-2653
User ID	Jennifer Kummerfeldt
Facility ID	2077

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Shannon Little
Title	Manager
Email	shannon.little@ascension.org
Phone	(316)-268-5854
User ID	Keisha Humphries
Facility ID	1869

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Shannon Little
Title	Manager
Email	Shannon.little@ascension.org
Phone	(316)-268-5348
User ID	Keisha Humphries
Facility ID	1869

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Shannon Little
Title	Manager
Email	shannon.little@ascension.org
Phone	(316)-268-5348
User ID	Keisha Humphries
Facility ID	1869

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Shannon Little
Title	Manager
Email	shannon.little@ascension.org
Phone	(316)-268-5348
User ID	Keisha Humphries
Facility ID	1869

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Julie Jarvis
Title	Director of Operations
Email	julie.jarvis@integrishealth.org
Phone	(405)-773-6406
User ID	Nathaniel Moulton
Facility ID	2000

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jordan Fein, MD and Leslie Sorenson
Title	Medical Director and Manager
Email	lmsorens@lhs.org
Phone	(503)-413-8446
User ID	Leslie Sorenson
Facility ID	2065

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Danielle Henricksen
Title	Cancer Program Director
Email	Danielle.Henricksen@bryanhealth.org
Phone	(402)-481-7900
User ID	Angela Burchett
Facility ID	1929

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Danielle Henricksen
Title	Cancer Program Director
Email	Danielle.Henricksen@bryanhealth.org
Phone	(402)-481-7900
User ID	Angela Burchett
Facility ID	1929

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	No
Collect and review internal clinical outcomes in a quality improvement process.	No
Calculated Section Total	7
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Sharon Harms
Title	Radiology/GI Specialties Director
Email	Sharon.Harms@bryanhealth.org
Phone	(402)-481-3901
User ID	Angela Burchett
Facility ID	1929

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jillian Eastman
Title	Nurse Practitioner
Email	jeastman@hoacny.com
Phone	(315)-472-7504
User ID	Jillian Eastman
Facility ID	2064

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	No
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	6
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Andrea Gresnick
Title	CT Technologist
Email	agresnick@cassregional.org
Phone	(816)-887-0377
User ID	ANDREA GRESNICK
Facility ID	2070

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	No
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Andrea Gresnick
Title	CT Technologist
Email	agresnick@cassregional.org
Phone	(816)-887-0377
User ID	ANDREA GRESNICK
Facility ID	2070

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	No
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	6
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Andrea Gresnick
Title	CT Technologist
Email	agresnick@cassregional.org
Phone	(816)-887-0377
User ID	ANDREA GRESNICK
Facility ID	2071

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	No
Comments	Would like more information on this
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	Radloop
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Andrea Gresnick
Title	CT Technologist
Email	agresnick@cassregional.org
Phone	(816)-887-0377
User ID	ANDREA GRESNICK
Facility ID	2071

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1607

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1607

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1606

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1606

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1605

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1605

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1604

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1604

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1617

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1617

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1610

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1610

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1616

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1612

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1612

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1621

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1621

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1609

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1609

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1608

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1608

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1622

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1622

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1615

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1615

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1620

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1620

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1611

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1611

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1614

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1614

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1603

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	Leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1603

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1619

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1619

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1613

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1613

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@advocatehealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1618

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1618

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Leisa Lackey
Title	Director
Email	leisa.lackey@atriumhealth.org
Phone	(704)-446-8574
User ID	leisa lackey
Facility ID	1616

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Krystle Pew
Title	LCS Director
Email	Krystle.Pew@va.gov
Phone	(205)-933-8101
User ID	Sasha Smith
Facility ID	1812

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Deepankar Sharma
Title	Interventional Pulmonologist, Medical Director - Lung Institute
Email	dsharma@crh.org
Phone	(443)-835-5863
User ID	Deepankar Sharma
Facility ID	2063

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deepankar Sharma
Title	Interventional Pulmonologist, Medical Director - Lung Institute
Email	dsharma@crh.org
Phone	(443)-835-5863
User ID	Deepankar Sharma
Facility ID	2063

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Amie J. Miller
Title	APRN
Email	amie-miller@smh.com
Phone	(941)-917-6203
User ID	Amie Miller
Facility ID	1400

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	No
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Amie J. Miller Miller
Title	APRN
Email	amie-miller@smh.com
Phone	(941)-917-6203
User ID	Amie Miller
Facility ID	1400

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jenn Bainey
Title	Lung Health Navigator
Email	jbainey@conemaugh.org
Phone	(814)-534-5212
User ID	Jenn Bainey
Facility ID	1627

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jenn Bainey
Title	Lung Health Navigator
Email	jbainey@conemaugh.org
Phone	(814)-534-5212
User ID	Jenn Bainey
Facility ID	1243

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Tram Nguyen
Title	NP
Email	tram.nguyen4@va.gov
Phone	(858)-642-3917
User ID	Lana Sheinkman
Facility ID	1851

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jordan Fein, MD and Leslie Sorenson
Title	Director and Manager
Email	lmsorens@lhs.org
Phone	(503)-413-8050
User ID	Leslie Sorenson
Facility ID	1858

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jordan Fein, MD and Leslie Sorenson
Title	Director and Manager
Email	lmsorens@Lhs.org
Phone	(503)-413-8050
User ID	Leslie Sorenson
Facility ID	1716

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Jordan Fein, MD and Leslie Sorenson
Title	Director and Manager
Email	lmsorens@lhs.org
Phone	(503)-413-8050
User ID	Leslie Sorenson
Facility ID	1123

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Jackie Muenks
Title	Director Outpatient Radiology
Email	Jackie.Muenks@coxhealth.com
Phone	(417)-268-8543
User ID	Kim McMillian
Facility ID	1751

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Lisa Allen
Title	Thoracic & Foregut Oncology Navigator
Email	lallen@mercy.com
Phone	(513)-215-9766
User ID	Marquisse Watson
Facility ID	1358

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Nicole Vogelsang
Title	Lung Navigator
Email	nrvogelsang@mercy.com
Phone	(513)-478-7706
User ID	Marquisse Watson
Facility ID	1358

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Comments	Fleischner criteria as reviewed by dedicated Thoracic radiologists
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Comments	Multidisciplinary Thoracic Oncology tumor board with Thoracic Radiology, Thoracic surgery, Radiation Oncology, Interventional Pulmonology, Thoracic Oncology and Pathology
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Comments	EMR-based solution with documentation of Tumor Board input and reporting to referring physicians.
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Comments	Routine component of standardized Interventional Pulmonary clinic assessment
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	Epic alerts are used to alert ordering providers if an incidental nodule warranting follow up is present with specific recommendations for follow-up (e.g. refer to Pulmonology, Thoracic surgery, etc)
Institutional tools are engaged to ensure all IPNs are identifed and managed.	No
Name	Vivek Murthy, MD
Title	Director, Bellevue Lung Cancer Screening Program
Email	murthyv@nychhc.org
Phone	(347)-346-3776
User ID	Vivek Murthy
Facility ID	1999

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	USPSTF Criteria
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	Shared decision making documentation is required to proceed with LCS, embedded into our EMR orderset and documented in a standardized note for all patients.
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	LungRADS standard reporting
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Bellevue Thoracic Oncology Tumor Board review of all screen-positive cases involving Thoracic surgery, Thoracic radiology, Radiation Oncology, Thoracic Oncology, Interventional Pulmonology and Pathology in addition to the LCS Navigator.
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Comments	EMR-based standardized workflow
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Comments	Cessation services offered within a dedicated LCS clinic.
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Comments	EMR-based solution for centralized (system-wide) monitoring of results, follow-up plan and alerts when scans/interventions are due.
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Comments	EMR-based solution (Epic Lung nodule)
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Vivek Murthy
Title	Director, Bellevue Lung Cancer Screening Program
Email	murthyv@nychhc.org
Phone	(347)-346-3776
User ID	Vivek Murthy
Facility ID	1999

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	We screen BTMed pts but do not send them to ACR NRDR LCSR
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	No
Comments	Smoking Cessation is managed by PC and Pulm. We are currently working on cessation brochure for imaging sites
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	8
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Comments	LCSR
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Comments	annually
Name	Trent West
Title	Lung Screening Manager
Email	t1west@saint-lukes.org
Phone	(913)-940-1191
User ID	Trent West
Facility ID	1629

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	No
Comments	Unknown
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	No
Comments	Unknown
Name	Ashley Nettles
Title	LCS Coordianator
Email	ashgraff@med.umich.edu
Phone	(734)-998-6326
User ID	Ashley Nettles
Facility ID	1962

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jennifer Hellmuth
Title	RN Navigator
Email	jhellmut@med.umich.edu
Phone	(734)-936-5661
User ID	Ashley Nettles
Facility ID	1962

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
Comments	SDM prior to order placement and DT when scheduling
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Comments	Prior to order placement
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Comments	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Comments	LungRads
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Comments	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Ashley Nettles
Title	LCS Coordinator
Email	ashgraff@med.umich.edu
Phone	(734)-998-6326
User ID	Ashley Nettles
Facility ID	1962

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Laura Kuzma MSW
Title	Administrative Director, Oncology Services
Email	lkuzma@firsthealth.org
Phone	(910)-715-2298
User ID	Kim Cobb
Facility ID	1296

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Comments	In process of applying for ACR accreditation as well and will then be reporting to ACR registry
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Comments	We do so at weekly huddles and via Epic Lung
Name	Alfredo Astua
Title	Chief of Pulmonary and Critical Care
Email	astuaa@nychhc.org
Phone	(917)-957-2242
User ID	alfredo astua
Facility ID	2052

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	No
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Joanna Thompson
Title	Director, LCSP & Multidisciplinary Programs
Email	jthompson@hogonc.com
Phone	(479)-587-1700
User ID	Joanna Thompson
Facility ID	1126

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Lacey Phelps
Title	Oncology Clinical Practice Manager
Email	phelln@mchealth.net
Phone	(270)-745-1069
User ID	Jennifer Finch
Facility ID	2029

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	No
Comments	We have board certified cardiothoracic surgeons but they are not Thoracic oncologists
Name	Lacey Phelps
Title	Oncology Clinical Practice Manager
Email	phelln@mchealth.net
Phone	(270)-745-1069
User ID	Jennifer Finch
Facility ID	2029

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	No
Name	Alexis B. Paulson, MSN, APRN
Title	Lung Screening Program Coordinator
Email	alexis.paulson@commonspirit.org
Phone	(805)-346-3463
User ID	Alexis Paulson
Facility ID	1301

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Jennifer Finch
Title	VP of Supply Chain
Email	fincjl@mchealth.net
Phone	(270)-745-1224
User ID	Jennifer Finch
Facility ID	2029

Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies.	Yes
Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results.	Yes
When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated.	Yes
In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option.	Yes
In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option.	Yes
Calculated Section Total	5
Qualification Status	Qualified
Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield.	Yes
Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression.	Yes
Name	Keaona Adkinson
Title	Director of Oncology Services
Email	keaona_adkinson@grandviewhealth.com
Phone	(205)-971-1802
User ID	Kristi Denny
Facility ID	1873

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Internal clinical outcomes review and quality improvement process.	Yes
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Name	Keaona Adkinson
Title	Director of Oncology
Email	keaona_adkinson@grandviewhealth.com
Phone	(205)-971-1802
User ID	Kristi Denny
Facility ID	1873

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Kristi Denny
Title	Navigator
Email	kristi_denny@grandviewhealth.com
Phone	(205)-971-1805
User ID	Kristi Denny
Facility ID	1873

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Keaona Adkinson
Title	Director of Oncology
Email	keaona_adkinson@grandviewhealth.com
Phone	(205)-971-1802
User ID	Kristi Denny
Facility ID	1873

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Catrina Linn Mellen Gilstrap
Title	Nurse Navigator
Email	catrina.gilstrap@mercy.net
Phone	(417)-556-2714
User ID	Catrina Gilstrap
Facility ID	1429

Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines.	Yes
Comments	We utilize Fleischner Society Guidelines.
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings.	Yes
Comments	Weekly lung nodule team conference with pulmonary, interventional pulmonary, thoracic surgery, navigation.
Commitment to a standardized process for communication with patients and their active care providers about test results and management plan.	Yes
Comments	Utilizing the EON platform for IPN we have standardized templated letters that both patients and providers receive upon identification of a IPN that is consider of high risk an needs to be followed.
Ask about current smoking status and advise to quit. Provide or refer for cessation services.	Yes
Comments	Upon verification of current smoking status patients are advised to quit and are given appropriate resources to free services.
Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology.	Yes
Comments	As per on our radiology reports, This exam was performed according to our departmental dose-optimization program which includes automated exposure control, adjustment of the mA and/or kV according to patient size and/or use of iterative reconstruction technique.
Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines.	Yes
Comments	We unitize the EON tracking software to ensure proper follow up and adherence to guidelines
Internal clinical outcomes review and quality improvement process.	Yes
Comments	Quarterly adherence reports provided by EON software, along with metrics from the time finding to definitive treatment are reviewed routinely for quality improvement.
Calculated Section Total	7
Qualification Status	Qualified
Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management.	Yes
Comments	Most IPN are captured with the EON AI software. With other IPN entering the program Other points of enter exist however, work flows are not as streamlined and rely on word of mouth, facts, phone call or email notification. We hope to improve this process once our health care system fully integrates into the EPIC EMR.
Institutional tools are engaged to ensure all IPNs are identifed and managed.	Yes
Comments	We utilize the EON platform for all tracking and identifying of IPNs
Name	Rona Seiple
Title	Incidental Pulmonary Nodule Program Coordinator
Email	rona-seiple@smh.com
Phone	(941)-917-6236
User ID	Rona Seiple
Facility ID	1400

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Maggie Smith
Title	RN/Director
Email	margaret.smith610@commonspirit.org
Phone	(502)-507-5715
User ID	Emily May
Facility ID	1468

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Maggie Smith
Title	RN/Director
Email	margaret.smith610@commonspirit.org
Phone	(502)-507-5715
User ID	Emily May
Facility ID	1468

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1469

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1567

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1250

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Maggie Smith
Title	RN/Director
Email	margaret.smith610@commonspirit.org
Phone	(502)-507-5715
User ID	Emily May
Facility ID	1255

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Maggie Smith
Title	RN/Director
Email	margaret.smith610@commonspirit.org
Phone	(502)-507-5715
User ID	Emily May
Facility ID	1255

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1254

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1252

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1256

A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies.	Yes
Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual.	Yes
Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan.	Yes
Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER)	Yes
Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services.	Yes
Calculated Section Total	10
Qualification Status	Qualified
Internal clinical outcomes review and quality improvement process.	Yes
Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons.	Yes
Name	Maggie Smith
Title	RN
Email	margaret.smith610@commonspirit.org
Phone	(502)-507-5715
User ID	Emily May
Facility ID	1251

Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility.	Yes
A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum.	Yes
Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters.	Yes
Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP).	Yes
Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process.	Yes
Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan.	Yes
Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate.	Yes
Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening.	Yes
Collect and review internal clinical outcomes in a quality improvement process.	Yes
Calculated Section Total	9
Qualification Status	Qualified
Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other).	Yes
Monitor for lung cancer stage shift among screen-detected lung cancers.	Yes
Name	Deanna Wigginton
Title	APRN
Email	deanna.wigginton@commonspirit.org
Phone	(859)-421-6195
User ID	Emily May
Facility ID	1251

Thoracic Oncology: Compliance with practice
A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey.	Yes
Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies.	Yes
Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes
Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment.	Yes

Need more information?

Sign up for the latest news.

Success!

Thank you for subscribing!